Patents Examined by Terra C. Gibbs
  • Selective antisense compounds and uses thereof
    Patent number: 10202599
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: February 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Eric E. Swayze
  • Methods of using microRNA-141
    Patent number: 10202604
    Abstract: Provided herein are methods of treating a cancer in an individual. A microRNA-141 oligonucleotide or mimic that increases the expression of microRNA-141 in the cancer cell is administered to the individual. Also provided is a method of inhibiting proliferation of a cancer cell and treating a cell associated with a cancer. The cell is contacted with the microRNA-141 oligonucleotide or mimic.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 12, 2019
    Assignee: Stemirna Therapeutics Co., Ltd.
    Inventors: Dean Tang, Can Liu
  • Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
    Patent number: 10195247
    Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Zhigang He, Duo Jin, Fang Sun
  • Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
    Patent number: 10174324
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 8, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • MiRNA for treating head and neck cancer
    Patent number: 10174314
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA-323, miRNA-342, miRNA-326, miRNA-371, miRNA-3157 and/or miRNA-345 molecule, an equivalent or a source thereof in a disease and condition associated with a squamous cell carcinoma such as head and neck cancer or a preneoplastic mucosal change.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 8, 2019
    Assignees: INTERNA TECHNOLOGIES B.V., VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
    Inventors: Rudolf Henrikus Brakenhoff, Marlon Van Der Plas, Sanne Rosaly De Kemp, Willemijn Maria Gommans, Grégoire Pierre André Prevost, Roeland Quirinus Jozef Schaapveld, Francesco Cerisoli
  • Particles comprising single stranded RNA and double stranded RNA for immunomodulation
    Patent number: 10172960
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 8, 2019
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • PCSK9 iRNA compositions and methods of use thereof
    Patent number: 10125369
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 13, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Anna Borodovsky, Kallanthottathil G. Rajeev, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • Hippo and dystrophin complex signaling in cardiomyocyte renewal
    Patent number: 10119141
    Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: November 6, 2018
    Assignees: Baylor College of Medicine, Texas Heart Institute
    Inventors: James F. Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
  • Methods used to treat cancer
    Patent number: 10119137
    Abstract: The invention encompasses methods used in the sensitization and treatment of cancer based upon the expression of SGEF.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: November 6, 2018
    Assignee: The Translational Genomics Research Institute
    Inventor: Nhan Tran
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 10106798
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Apoptosis inducer
    Patent number: 10093931
    Abstract: The purpose of the present invention is to provide: a composition for effectively inducing apoptosis and/or proliferation inhibition in cells; and a method in which the composition is used. The present invention relates to: an agent for inducing apoptosis, which contains a GST-?-inhibiting drug and a RB1CC1-inhibiting drug as active ingredients; a pharmaceutical composition which contains the agent; a method for treating a disease associated with an abnormality in apoptosis, in which the agent is used; and others.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: October 9, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Hiroyuki Tanaka
  • Method of promoting wound healing
    Patent number: 10071115
    Abstract: Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 11, 2018
    Assignee: Agency for Science, Technology and Research
    Inventor: Prabha Sampath
  • Modulators of the interaction of astrin and raptor, and uses thereof in cancer therapy
    Patent number: 10041933
    Abstract: The present invention relates to modulators of the interaction of astrin and raptor, and their uses in the treatment of mTOR related diseases, such as cancer.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: August 7, 2018
    Assignee: ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG
    Inventors: Kathrin Thedieck, Birgit Holzwarth, Ralf Baumeister
  • Oligomeric compounds comprising bicyclic nucleotides and uses thereof
    Patent number: 10017764
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: July 10, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
    Patent number: 10011837
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: July 3, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
    Patent number: 10011832
    Abstract: The present invention relates to methods, compositions and dosages that decrease IOP of the eye, comprising a 19 nucleotide double-stranded RNA molecule.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: July 3, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez Anton, Victoria Gonzalez Fajardo, Veronica Ruz Palomar
  • Compositions and methods to promote erythropoiesis
    Patent number: 9988633
    Abstract: Described herein are compositions and methods for enhancing erythropoiesis in an individual in need thereof. Specifically agents that decrease the expression of Exosc10, such as inhibitory nucleic acid molecules, produce an increase in red blood cell production in the individual.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 5, 2018
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Emery H. Bresnick, Yoon A. Kang, Skye McIver
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 9988635
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 5, 2018
    Assignee: Antisense Therapeutics Limited
    Inventor: George Tachas
  • Antisense antiviral compounds and methods for treating a filovirus infection
    Patent number: 9982261
    Abstract: The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 29, 2018
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Patrick L. Iversen, Dwight D. Weller
  • Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
    Patent number: 9970012
    Abstract: The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: May 15, 2018
    Assignee: Raadysan Biotech, Inc.
    Inventor: Rakhee S. Gupte